The article highlights how SmileFy bridges the gap between digital smile simulation and clinical delivery. By combining AI visualization with guided 3D planning, SmileFy enables predictable outcomes, ...
Biotech data visualization is often static and fragmented, limiting the ability to see integrated patient journeys and ...
PALO ALTO, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--While clinical development technologies have come a long way in recent years, research sponsors continue to struggle to connect disparate systems ...
Zacks Investment Research on MSN
QT Imaging & Olea Medical partner to enhance cloud imaging platform
QT Imaging Holdings, Inc. QTIH recently announced a collaboration with Olea Medical aimed at enhancing visualization, ...
This collaboration enhances QT Imaging's Cloud SaaS Platform by integrating Olea Medical's advanced visualization, quantitative analytics and AI-ready imaging technologies to support clinical ...
Benefits and Barriers of Technology for Home Function and Mobility Assessment: Perspectives of Older Patients With Blood Cancers, Caregivers, and Clinicians Clinical trial adverse event (AE) data are ...
News Medical on MSN
New oral contrast agent improves bowel disease detection on CT scans
In a new pilot feasibility study, researchers from Mayo Clinic, the University of Washington School of Medicine, the University of California San Francisco, and Nextrast Inc. found that a new imaging ...
If there’s one thing that characterizes the Information Age that we find ourselves in today, it is streams of data. However, without proper ways to aggregate and transform this data into information, ...
The medical holography market is projected to grow at a robust CAGR of approximately 29% through 2029. This growth is driven ...
Editor’s note: This is the third article in a four-part series that is part of a larger initiative the AICPA Auditing Standards Board (ASB) has undertaken to understand and support technology use in ...
In todays pharmaceutical executive daily, Mirum Pharmaceuticals strengthens its rare disease portfolio through a $268 million ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results